文献速递流行病学与生物统计临床试验与 GCP

疑似心肌梗死患者0/1 h与0/3 h路径性能:随机试验个体数据荟萃分析

Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2026-10-29

该系统综述与个体参与者数据荟萃分析纳入5项随机试验共110 933例就诊,比较0/1 h与0/3 h路径。30天全因死亡或新发1型心肌梗死合并OR 0·83(95%CI 0·45-1·53),急诊停留时间几何均数比1·03(95%CI 0·85-1·25),直接出院OR 1·31(95%CI 0·79-2·16)。

要点

  • 0/1 h与0/3 h路径30天安全结局合并估计无显著差异,但精度有限。
  • 更早复测肌钙蛋白未缩短急诊停留时间,也未明确提高直接出院率。
  • 研究间异质性显著,路径效果在不同医疗体系间可能不一致。

核心结论

  • 现有随机试验中两种路径短期不良事件率均低,但合并安全性估计不精确。
  • 更早复测肌钙蛋白平均未减少急诊停留时间,也未明确增加直接出院。
  • 显著的研究间异质性提示治疗效果在不同医疗体系间可能不一致。

研究设计与样本

  • 系统综述与个体参与者数据荟萃分析,检索PubMed、Cochrane CENTRAL、Scopus及ICTRP至2026年7月6日,无语言限制。
  • 纳入比较0/1 h与0/3 h路径安全性和有效性的随机试验,共5项试验、110 933例就诊(0/1 h组55 489例,0/3 h组55 444例)。
  • 主要分析采用两阶段随机效应荟萃分析,主要安全结局为30天内全因死亡或新发1型心肌梗死复合终点。
  • 主要疗效结局为急诊停留时间和急诊直接出院,方案注册于PROSPERO(CRD420261383452)。

主要发现

  • 30天内全因死亡或新发1型心肌梗死:0/1 h组446例(0·8%),0/3 h组562例(1·0%),合并OR 0·83(95%CI 0·45-1·53),I2=62·9%,τ2=0·143。
  • 急诊停留时间:0/1 h组314 min(IQR 211-481),0/3 h组308 min(IQR 209-453),合并几何均数比1·03(95%CI 0·85-1·25),I2=99·2%,τ2=0·024。
  • 急诊直接出院:0/1 h组37 190例(67·0%),0/3 h组36 485例(65·8%),合并OR 1·31(95%CI 0·79-2·16),I2=97·8%,τ2=0·156。
  • 5项试验中主要安全结局定义不一致,4项试验未报告全分析人群的急诊停留时间。

关键数值与推荐

  • 30天全因死亡或新发1型心肌梗死合并OR 0·83(95%CI 0·45-1·53),基于110 933例就诊。
  • 急诊停留时间合并几何均数比1·03(95%CI 0·85-1·25),基于可分析人群。
  • 急诊直接出院合并OR 1·31(95%CI 0·79-2·16),0/1 h组67·0% vs 0/3 h组65·8%。

临床怎么用

  • 医院从0/3 h向0/1 h路径转换时,应结合更广泛的诊断和组织因素做实施决策。
  • 不应仅依据更早复测肌钙蛋白预期缩短急诊停留时间或提高直接出院率。
  • 解读合并安全性估计需考虑研究间异质性和置信区间较宽。

局限性

  • 仅纳入5项随机试验,主要安全结局定义在各试验间不一致。
  • 4项试验未报告全分析人群的急诊停留时间。
  • 主要安全结局在获取个体数据后、数据协调或分析前由原复合终点细化。
  • 研究间异质性显著(I2最高达99·2%),合并估计精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with suspected myocardial infarction, the 0/1 h pathway (blood draws at 0 h and 1 h) is recommended in current guidelines for early risk stratification. However, individual trials used different safety outcomes, and efficacy outcomes were inconclusive or not assessed. We conducted a systematic review and individual participant data meta-analysis of all randomised controlled trials to synthesise the totality of the evidence, assess heterogeneity across trials, and evaluate clinically relevant outcomes using harmonised definitions across trials. METHODS: In this systematic review and individual participant data meta-analysis, we searched PubMed, Cochrane Central Register of Controlled Trials, Scopus, and the International Clinical Trials Registry Platform from inception to July 6, 2026, without language restrictions, for randomised trials comparing the safety and efficacy of 0/1 h versus 0/3 h pathways (blood draws at 0 h and 3 h, ie, standard care). Individual participant data were obtained and outcome definitions were harmonised. The primary analysis used a two-stage random-effects meta-analysis. After receipt of the individual participant data but before data harmonisation or analysis, the primary safety outcome was refined to a composite of all-cause death or new type 1 myocardial infarction within 30 days, from the originally specified composite of all-cause death or any new myocardial infarction. The primary efficacy outcomes were emergency department length of stay and direct discharge from the emergency department. This meta-analysis is registered with PROSPERO (CRD420261383452). FINDINGS: Our systematic review identified five randomised trials, all of which provided individual participant data. Among these, the definition of the primary safety outcome varied, and in four trials emergency department length of stay was not reported for the whole analysis population. We included 110 933 patient presentations (55 489 managed with the 0/1 h pathway and 55 444 managed with the 0/3 h pathway). Within 30 days, all-cause death or new type 1 myocardial infarction occurred in 446 patient presentations (0·8%) with the 0/1 h pathway versus 562 patient presentations (1·0%) with the 0/3 h pathway (random-effects pooled odds ratio [OR] 0·83 [95% CI 0·45-1·53]; I2=62·9%; τ2=0·143). Emergency department length of stay was 314 min (IQR 211-481) in the 0/1 h pathway group versus 308 min (209-453) in the 0/3 h pathway group (random-effects pooled geometric mean ratio 1·03 [95% CI 0·85-1·25]; I2=99·2%; τ2=0·024). Direct discharge from the emergency department occurred in 37 190 patient presentations (67·0%) with the 0/1 h pathway versus 36 485 patient presentations (65·8%) with the 0/3 h pathway (random-effects pooled OR 1·31 [95% CI 0·79-2·16]; I2=97·8%; τ2=0·156). INTERPRETATION: Across the available randomised trials, short-term adverse event rates were low with both pathways, but the pooled safety estimate remained imprecise. On average, earlier cardiac troponin retesting did not reduce emergency department length of stay or clearly increase direct discharge, and substantial between-study heterogeneity indicates that treatment effects might not translate uniformly across health-care systems. For hospitals considering transitioning from a 0/3 h to a 0/1 h pathway, implementation decisions should take broader diagnostic and organisational considerations into account. FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, University Hospital Basel, University of Basel, and Foundation for Cardiovascular Research Basel.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Boeddinghaus J, Kunz M, Lopez-Ayala P, et al. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials. Lancet. 2026. PMID: 42956796. doi:10.1016/S0140-6736(26)01767-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。